News

Endpoints News1h
Aldeyra plots third FDA fil­ing for dry eye dis­ease drug af­ter lat­est Phase 3 da­ta
Aldeyra Therapeutics reports Phase 3 success with reproxalap for dry eye disease, plans third FDA filing after previous ...
Endpoints News7h
Sin­ga­pore car­dio gene ther­a­py biotech col­lects $45M as it plots Eu­rope ex­pan­sion
A Singapore-based startup raised a $45 million Series B to start testing a gene therapy in humans next year for a genetic ...
Endpoints News13h
Ver­tex touts promis­ing first few months of launch for non-opi­oid pain drug Jour­navx
Vertex said it's gathering momentum with its new product launches, building out new franchises with its sickle cell therapy ...
Endpoints News15h
New opi­oid da­ta may not be gen­er­al­iz­able, FDA ad­comm says
Several members of an FDA advisory committee warned on Monday that new data from studies on long-term use of opioids might ...
Endpoints News16h
PTC's Hunt­ing­ton’s study suc­ceeds, but ac­cel­er­at­ed ap­proval un­cer­tain
PTC Therapeutics announced Monday that its splicing drug for Huntington’s disease met the primary endpoint of a Phase 2 study ...
Endpoints News20h
Func­tion buys Ezra, cre­at­ing one-stop shop for pre­ven­tive test­ing and scans
Function Health is buying Ezra in a bid to create a haven for people who want copious amounts of data on their bodies. The ...
Endpoints News21h
Re­cur­sion cuts near­ly half of its pipeline, in­clud­ing its most ad­vanced pro­gram
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Endpoints News23h
J&J's eye dis­ease gene ther­a­py bo­ta-vec fails in Phase 3 tri­al
J&J's gene therapy bota-vec failed Phase 3 trial for X-linked retinitis pigmentosa vision loss. Follows trend of big pharma ...